XOMA Royalty Corporation Common Stock
XOMA Real Time Price USDRecent trades of XOMA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in XOMA holdings by institutional investors
Quarterly net insider trading by XOMA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$30,000 Jan 20, 2016 Issue: None
-
$60,000 Aug 24, 2015 Issue: Health Issues
-
$30,000 Aug 04, 2015 Issue: Health Issues
-
$110,000 Apr 20, 2015 Issue: Taxation/Internal Revenue Code Health Issues
-
$30,000 Jan 16, 2015 Issue: Health Issues Taxation/Internal Revenue Code
-
$50,000 Oct 20, 2014 Issue: Taxation/Internal Revenue Code Health Issues
-
$20,000 Aug 14, 2014 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code
-
$20,000 Jan 19, 2012 Issue: Defense
-
$30,000 Oct 20, 2011 Issue: Homeland Security Defense Copyright/Patent/Trademark Budget/Appropriations
-
$80,000 Jul 20, 2011 Issue: Defense Copyright/Patent/Trademark Health Issues Budget/Appropriations Homeland Security
-
$80,000 Apr 19, 2011 Issue: Health Issues Defense Copyright/Patent/Trademark Budget/Appropriations
-
$40,000 Jan 19, 2011 Issue: Health Issues Defense Budget/Appropriations
-
$60,000 Oct 20, 2010 Issue: Budget/Appropriations Health Issues Defense
-
$120,000 Oct 19, 2010 Issue: Defense Budget/Appropriations
-
$120,000 Jul 19, 2010 Issue: Financial Institutions/Investments/Securities Defense Homeland Security Health Issues Budget/Appropriations
-
$50,000 Jan 20, 2010 Issue: Defense Budget/Appropriations
-
$90,000 Oct 19, 2009 Issue: Medical/Disease Research/Clinical Labs Defense
-
$120,000 Jul 20, 2009 Issue: Defense
-
$130,000 Apr 16, 2009 Issue: Defense
-
$260,000 Jan 21, 2009 Issue: Defense Medical/Disease Research/Clinical Labs
-
$150,000 Oct 16, 2008 Issue: Medical/Disease Research/Clinical Labs Defense
-
$180,000 Oct 16, 2008 Issue: Medical/Disease Research/Clinical Labs Defense
-
$150,000 Apr 21, 2008 Issue: Science/Technology Pharmacy Taxation/Internal Revenue Code Disaster Planning/Emergencies Homeland Security
-
$120,000 Feb 12, 2008 Issue: Homeland Security Disaster Planning/Emergencies Science/Technology Taxation/Internal Revenue Code Pharmacy
-
$100,000 Feb 14, 2007 Issue: Government Issues
-
$100,000 Aug 17, 2006 Issue: Government Issues
-
$80,000 Feb 17, 2006 Issue: Government Issues
-
$20,000 Aug 15, 2005 Issue: Government Issues
XOMA Estimated quarterly lobbying spending
XOMA Revenue by Segment or Geography
New XOMA patent grants
-
Patent Title: Modulators Jul. 29, 2025
-
Patent Title: Antibodies that bind interleukin-2 and uses thereof Feb. 25, 2025
-
Patent Title: Antibodies that bind transforming growth factor beta (tgf beta) and methods of use thereof for treatment Aug. 27, 2024
-
Patent Title: Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof Oct. 17, 2023
-
Patent Title: Method of increasing the ratio of effector t cells to regulatory t cells in a tumor by administering to a subject a tgf-beta inhibitor and a pd-1 antibody Jun. 27, 2023
-
Patent Title: Compositions and methods for delaying the incidence of labor Dec. 27, 2022
-
Patent Title: Modulators Mar. 01, 2022
-
Patent Title: Method of treating cancer by administering an antibody that binds transforming growth factor beta (tgf-beta) 1, tgf-beta 2 and tgf-beta 3 Aug. 24, 2021
-
Patent Title: Antibodies that bind interleukin-2 and uses thereof Dec. 08, 2020
-
Patent Title: Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery Jul. 14, 2020
-
Patent Title: Treatment of cancer using anti-tgf-β and anti-pd-1 antibodies Jun. 16, 2020
-
Patent Title: Modulators Apr. 17, 2018
-
Patent Title: Screening methods Feb. 06, 2018
-
Patent Title: Methods and materials for enhancing functional protein expression in bacteria Aug. 15, 2017
-
Patent Title: Modulators Aug. 08, 2017
-
Patent Title: Tgf-beta-specific antibodies and methods of use thereof for treatment Jul. 25, 2017
-
Patent Title: Pharmaceutical compositions comprising il-1b binding antibodies and fragments thereof Dec. 08, 2015
-
Patent Title: Methods for the treatment of il-1β related diseases Oct. 20, 2015
-
Patent Title: Antibodies specific for tgf-β and methods of treatment thereof Sep. 29, 2015
-
Patent Title: Methods for the treatment of uveitis with il-1β binding antibodies Sep. 22, 2015
-
Patent Title: Methods and materials for targeted mutagenesis Aug. 11, 2015
-
Patent Title: Modulators Jan. 06, 2015
-
Patent Title: Anti-botulism antibody coformulations Sep. 02, 2014
-
Patent Title: Methods for the treatment of gout Jan. 28, 2014
-
Patent Title: Methods for the treatment of il-1β related diseases Nov. 19, 2013
-
Patent Title: Flexible manufacturing system Nov. 19, 2013
-
Patent Title: Antibodies specific for tgf-beta and methods for treating thereof Oct. 29, 2013
-
Patent Title: Methods for the treatment of il-1β related conditions Oct. 08, 2013
-
Patent Title: Triple tag sequences and methods of use thereof Oct. 01, 2013
-
Patent Title: Triple tag sequence and methods of use thereof Oct. 01, 2013
-
Patent Title: Methods for treating il-1β related diseases by administering an anti-il-1β antibody Oct. 01, 2013
-
Patent Title: Methods and materials for increasing expression of recombinant polypeptides Jul. 30, 2013
-
Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 02, 2013
-
Patent Title: Method of treating inflammatory eye disease with il-1β binding antibodies Feb. 19, 2013
-
Patent Title: Methods for improvement of beta cell function with anti-il-1β antibodies or fragments thereof Feb. 19, 2013
-
Patent Title: Antibodies to high molecular weight melanoma associated antigen Nov. 27, 2012
-
Patent Title: Methods for the treatment of il-1β related diseases Jan. 24, 2012
-
Patent Title: Methods and materials for increasing expression of recombinant polypeptides Aug. 09, 2011
-
Patent Title: Method of treating an il-1 related coronary condition Aug. 02, 2011
-
Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 12, 2011
-
Patent Title: Eukaryotic signal sequences for polypeptide expression and polypeptide display libraries Jul. 05, 2011
-
Patent Title: Il-1β binding antibodies and fragments thereof May. 17, 2011
-
Patent Title: Method of treating an il-1 related cancer Nov. 09, 2010
-
Patent Title: Method of treating an il-1 related autoimmune disease or condition Nov. 09, 2010
-
Patent Title: Methods and materials for expression of a recombinant protein Sep. 14, 2010
-
Patent Title: Methods for recombinant peptide production Jul. 06, 2010
-
Patent Title: Il-1β binding antibodies and binding fragments thereof Jun. 29, 2010
-
Patent Title: Il1-β binding antibodies and fragments thereof Jun. 29, 2010
-
Patent Title: Methods for the treatment of il-1β related diseases Apr. 13, 2010
-
Patent Title: Method of treating an il-1 related inflammatory disease or condition Apr. 13, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded to XOMA from public contracts
Recent insights relating to XOMA
Recent picks made for XOMA stock on CNBC
ETFs with the largest estimated holdings in XOMA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $XOMA stock a Buy, Sell, or Hold?
- What is the price target for $XOMA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $XOMA stock?
- Who owns the most shares of $XOMA stock?
- What funds own $XOMA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XOMA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
- Address Emeryville, CA
- Market Cap 404.2 million
- Employees 13
- Industrial Classification Pharmaceutical Preparations